DivestmentJun 1, 2026, 09:58 AM
Waldencast Sells Obagi Medical to Bridgepoint for up to $460M
AI Summary
Waldencast plc announced a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint for up to $460 million. This strategic divestment aims to strengthen Waldencast's balance sheet by repaying approximately $178 million in senior secured term loans and to allow the company to focus on accelerating the global growth of its remaining brand, Milk Makeup. Waldencast founders Michel Brousset and Hind Sebti will transition to lead Obagi Medical, while Felipe Dutra will become Waldencast's Executive Chairman.
Key Highlights
- Waldencast to sell Obagi Medical to Bridgepoint for up to $460 million.
- Transaction aims to strengthen Waldencast's balance sheet and focus on Milk Makeup.
- Waldencast expects to repay approximately $178 million of senior secured term loan.
- Founders Michel Brousset and Hind Sebti will transition to lead Obagi Medical.
- Felipe Dutra appointed Executive Chairman of Waldencast, effective immediately.
- Transaction is expected to close within the third quarter of 2026.
- Milk Makeup generated $110.4 million net revenue and $15.2 million Adjusted EBITDA in 2025.
Price Impact
More from WALD